MAZE
Maze Therapeutics, Inc.Company Information
- Company Name
- Maze Therapeutics, Inc.
- CIK
- CIK0001842295
- Category
- <br>Emerging growth company
- Ticker: Exchange
- MAZE: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- MAZE
SEC filing data through
Insider Sentiment
- Last purchase
- —
- Last sale
- 2026-09-04
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 550,668
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 55,536,782
- Shares outstanding
- 58,995,934
- Ownership
- 94.14%
Earnings Market Reaction
- Filing date
- 2026-08-11
- Price on filing date
- —
- 1-month reaction
- -4.03%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||
| Cash And Cash Equivalents At Carrying Value | 203 | 199 | 189 | 317 | 265 | 294 | ||||||
| Marketable Securities Current | 208 | 154 | 153 | 67 | - | - | ||||||
| Accounts Receivable Net Current | - | 20 | - | - | - | - | ||||||
| Prepaid Expense And Other Assets Current | 9 | 7 | 8 | 7 | 7 | 5 | ||||||
| Assets Current | 420 | 380 | 350 | 391 | 271 | 300 | ||||||
| Property Plant And Equipment Net | 4 | 5 | 5 | 6 | 6 | 6 | ||||||
| Restricted Cash Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Marketable Securities Noncurrent | 84 | 11 | 18 | - | - | - | ||||||
| Operating Lease Right Of Use Asset | 18 | 19 | 20 | 21 | 22 | 22 | ||||||
| Other Assets Noncurrent | 3 | 4 | 3 | 3 | 4 | 3 | ||||||
| Assets | 532 | 420 | 397 | 422 | 304 | 333 | ||||||
Liabilities Current | ||||||||||||
| Accounts Payable Current | 2 | 4 | 2 | 3 | 4 | 2 | ||||||
| Accrued Liabilities And Other Liabilities | 16 | 12 | 16 | 14 | 12 | 12 | ||||||
| Operating Lease Liability Current | 5 | 5 | 5 | 5 | 5 | 5 | ||||||
| Liabilities Current | 23 | 21 | 23 | 22 | 20 | 19 | ||||||
| Operating Lease Liability Noncurrent | 17 | 18 | 19 | 19 | 20 | 21 | ||||||
| Long Term Debt Noncurrent | 39 | 39 | - | - | - | - | ||||||
| Other Liabilities Noncurrent | - | 0 | 1 | 1 | 1 | 1 | ||||||
| Liabilities | 79 | 78 | 42 | 43 | 41 | 41 | ||||||
| Temporary Equity Carrying Amount Attributable To Parent | - | - | 0 | - | - | - | ||||||
Stockholders Equity | ||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 1,012 | 856 | 844 | 834 | 687 | 683 | ||||||
| Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax | -0 | -0 | 0 | 0 | - | - | ||||||
| Retained Earnings Accumulated Deficit | -558 | -514 | -490 | -455 | -425 | -391 | ||||||
| Stockholders Equity | 453 | 342 | 355 | 379 | 262 | 292 | ||||||
| Liabilities And Stockholders Equity | 532 | 420 | 397 | 422 | 304 | 333 | ||||||
| Preferred Stock Par Or Stated Value Per Share | - | - | - | - | - | 0.00 | ||||||
| Redeemable Convertible Preferred Stock | - | - | 0 | 0 | -33 | 33 | ||||||
| Preferred Stock | 0 | 0 | 0 | -0 | -33 | 33 | ||||||
| Preferred Stock Shares Authorized | - | - | - | - | - | 10 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 500 | 500 | 500 | 500 | 500 | 500 | ||||||
| Common Stock Shares Issued | 56 | 50 | 49 | 48 | 44 | 44 | ||||||
| Shares Outstanding | 56 | 50 | 49 | 48 | 44 | 44 | ||||||
Select a line item above to chart it.
Recent filings
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialMaze Therapeutics, Inc. (MAZE) — SEC Financial Statements & Analysis
Maze Therapeutics, Inc. (MAZE) is a biological products, (no diagnostic substances) company, incorporated in DE. Maze Therapeutics, Inc. trades on Nasdaq as: MAZE. Maze Therapeutics, Inc. (MAZE)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-11. Based on that filing, Maze Therapeutics, Inc. carries a market cap of $1.76B, a P/E ratio of -13.18x, a P/B ratio of 3.89x, a P/S ratio of 88.02x, an enterprise value of $1.60B, and an EV/EBITDA multiple of -11.11x. On profitability, it posts an operating margin of -728.06%, a net margin of -667.95%, a Return on Equity (ROE) of -37.35%, a Return on Assets (ROA) of -31.99%, and a Return on Invested Capital (ROIC) of -101.67%. Per share, it reports EPS of $-2.26, diluted EPS of $-2.26, free cash flow per share of $-1.81, and a dividend per share of $0.00. On the balance sheet, it maintains a current ratio of 18.31x, a quick ratio of 17.90x, working capital of $397.46M, a debt-to-equity ratio of 0.17x, a debt ratio of 0.15, an interest coverage ratio of -81.03x, free cash flow of $-106.84M (TTM), and net debt of $-163.68M. Figures sourced from SEC EDGAR.
- Market Cap
- $1.76B
- P/E TTM
- -13.18x
- EPS TTM
- $-2.26
- P/B TTM
- 3.89x
- ROE TTM
- -37.35%
- ROA TTM
- -31.99%
- Debt To Equity
- 0.17x
- Free Cash Flow TTM
- $-106.84M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Maze Therapeutics, Inc. in?
Maze Therapeutics, Inc. (MAZE) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does MAZE trade on?
Maze Therapeutics, Inc. (MAZE) trades on the Nasdaq.
Where is Maze Therapeutics, Inc. incorporated?
Maze Therapeutics, Inc. is incorporated in DE.
When was Maze Therapeutics, Inc. (MAZE)'s most recent SEC filing?
Maze Therapeutics, Inc. (MAZE)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-11.
What is MAZE's market cap?
Maze Therapeutics, Inc. (MAZE) has a market capitalization of $1.76B as of 2026-06-30.
What is MAZE's EPS (earnings per share)?
Maze Therapeutics, Inc. (MAZE)'s trailing twelve month EPS is $-2.26 as of 2026-06-30.
What is MAZE's ROE (return on equity)?
Maze Therapeutics, Inc. (MAZE)'s trailing twelve month Return on Equity (ROE) is -37.35% as of 2026-06-30.
What is MAZE's ROA (return on assets)?
Maze Therapeutics, Inc. (MAZE)'s trailing twelve month Return on Assets (ROA) is -31.99% as of 2026-06-30.
What is MAZE's ROIC (return on invested capital)?
Maze Therapeutics, Inc. (MAZE)'s trailing twelve month Return on Invested Capital (ROIC) is -101.67% as of 2026-06-30.
What is MAZE's EV/EBITDA?
Maze Therapeutics, Inc. (MAZE)'s trailing twelve month EV/EBITDA is -11.11x as of 2026-06-30.